Goodwin advised RA Pharmaceuticals on the deal Ra Pharmaceuticals, Inc. (NASDAQ: RARX) executed the pricing of an underwritten public offering of 8,400,000 shares of its common…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now